SIRPA and diffuse large B-cell lymphoma: The potential for a combined antagonism of CD47/SIRPα and PD‐1/PD‐L1 pathways is being evaluated in a Phase II study of TTI‐622 and TTI‐621 in combination with pembrolizumab for the treatment of R/R DLBCL (NCT05507541).